• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RadNet Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    3/2/26 7:00:48 AM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email
    RadNet, Inc. 8-K
    false 0000790526 0000790526 2026-03-02 2026-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) March 2, 2026

     

    RadNet, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33307   13-3326724
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer Identification No.)

     

    1510 Cotner Avenue    
    Los Angeles, California   90025
    (Address of Principal Executive Offices)   (Zip Code)

      

    Registrant’s Telephone Number, Including Area Code: (310) 478-7808

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.0001 par value RDNT NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 7.01. Regulation FD Disclosure.

     

    On March 2, 2026, RadNet, Inc., a Delaware corporation (“RadNet”) issued a press release announcing the acquisition of Gleamer SAS, a société par actions simplifiée formed under the laws of the Republic of France (“Gleamer”), through its wholly-owned subsidiary DH AI International Holdings, B.V., a private limited company registered in the Netherlands. The aggregate purchase price for the acquisition is approximately €230 million, consisting of approximately €215.0 million in cash at the closing of the acquisition, and a contingent payment of approximately €15.0 million in cash, subject to completion or satisfaction of certain milestones by Gleamer.

     

    A copy of the press release is attached hereto as Exhibit 99.1. The information contained in Item 7.01 of this Current Report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing of RadNet, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) The following exhibits are furnished herewith:

     

    Exhibit
    Number
      Description of Exhibit
    99.1  Press Release dated March 2, 2026.
    104  Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

     

     

     

     

     2 

     

     

    SIGNATURES

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Date: March 2, 2026 RadNet, Inc.  
         
           
      By: /s/ David J. Katz  
      Name: David J. Katz  
      Title: Executive Vice President, Chief Legal Officer and Corporate Secretary  

     

     

     

     

     

     

     

     

     

     

     

     

     3 

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

    Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of

    3/2/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

    Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio

    3/2/26 5:45:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    DeepHealth Achieves CE Mark for TechLive™ and Enables AWS Marketplace Deployment, Advancing Global Expansion of Multimodality Vendor-Agnostic Remote Scanning Solution

    SOMERVILLE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today announced that TechLive™, its FDA-cleared remote imaging and radiology management solution, has achieved CE marking, enabling European commercialization of the industry's first solution that extends oversight across MR, CT, PET/CT and ultrasound. Designed to expand imaging capacity and access to complex procedures, TechLive enables European healthcare providers to more effectively manage workforce needs and expand access to advanced imaging. Additionally, TechLive is now listed in AWS Marketplace to stream

    2/26/26 4:01:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $RDNT
    SEC Filings

    View All

    EVP, Chief Financial Officer Stolper Mark exercised 35,703 shares at a strike of $6.07, increasing direct ownership by 52% to 103,715 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    12/12/25 4:15:27 PM ET
    $RDNT
    Medical Specialities
    Health Care

    EVP and Chief Legal Officer Katz David Jeffrey exercised 3,396 shares at a strike of $29.44, increasing direct ownership by 5% to 71,577 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    12/12/25 4:15:08 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & COO-Eastern Operations Forthuber Stephen M sold $3,531,849 worth of shares (45,088 units at $78.33), decreasing direct ownership by 8% to 529,221 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    12/9/25 4:15:21 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:01:44 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:00:48 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    1/30/26 4:17:01 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

    Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of

    3/2/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

    Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio

    3/2/26 5:45:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Announces Date of its Fourth Quarter 2025 Financial Results Conference Call

    LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2025 financial results on Monday, March 2, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1753363&tp_key=503d78aa96 [viavid.webcast

    2/17/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care